top of page

Registry Impact

2500+

Registered Participants

328,000+

Survey Question Responses

700+

Healthcare Provider Listings

Your Data in Publication

The following publications resulted from access to your de-identified PSC Partners Registry data. 

2024. Patient-focused drug development in primary sclerosing cholangitis: Insights on patient priorities and involvement in clinical trials

2024. Caregiver-reported symptom burden and preferences for therapeutic goals in pediatric primary sclerosing cholangitis

2023. AASLD Liver Meeting Abstract and Poster: 4640-C: CAREGIVER-REPORTED SYMPTOM BURDEN AND PREFERENCES FOR THERAPEUTIC GOALS IN PEDIATRIC PRIMARY SCLEROSING CHOLANGITIS

2023. AASLD Liver Meeting Abstract and Poster: 4579-C: THE EXTERNALLY-LED PATIENT-FOCUSED DRUG DEVELOPMENT MEETING FOR PRIMARY SCLEROSING CHOLANGITIS: INSIGHTS ON PATIENT INVOLVEMENT IN CLINICAL TRIALS

2023. AASLD Liver Meeting Abstract and Poster: 4577-C: SYMPTOMS OF PRIMARY SCLEROSING CHOLANGITIS (PSC) IN THE LAST MONTH: PRELIMINARY DATA FROM THE PSC-PARTNERS PATIENT REPORTED OUTCOME MEASURE PROJECT

2023. AASLD Liver Meeting Abstract and Poster: 4558-C: NETWORK ANALYSIS OF SYMPTOMS EXPERIENCED BY PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS

2023. AASLD Liver Meeting Abstract and Poster: 3784-C: CENTERING THE PATIENT VOICE IN MULTI-STAKEHOLDER ENGAGEMENT TO DEVELOP A STRATEGIC RESEARCH PLAN FOR THE PSC COMMUNITY

2021. FINDINGS FROM THE PATIENT-FOCUSED DRUG DEVELOPMENT FORUM ON PRIMARY SCLEROSING CHOLANGITIS

2019. Pregnancy Experiences in Women with Primary Sclerosing Cholangitis

2019. Potential Association of Doxycycline With the Onset of Primary Sclerosing Cholangitis: A Case Series

2019. Clinical Characteristics and Outcomes Reported by Patients with Primary Sclerosing Cholangitis Through an Online Registry

2017. Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO

2016. Medical Treatments in Patients with Primary Sclerosing Cholangitis Differ Between Europe and North America

2016. Frequency of Familial Primary Sclerosing Cholangitis (PSC) and Inflammatory Bowel Disease: Results From the PSC Partners Patient Registry

2015. Characterization Of A Patient Driven International Registry For Primary Sclerosing Cholangitis

Advocacy

The Patient Registry enables advocacy on behalf of PSC patients.

Clinical Trial and Study Protocol:

PSC Partners is collaborating with pharmaceutical companies planning and conducting clinical trials by adding your patient perspective to the trial protocol. We also collaborate with researchers on their academic study protocols.

Communication of Trial and Study Opportunities with Patients:

Through the Patient Registry, we are able to share clinical-trial and study information with the PSC community. Those participants who have elected to receive notification from the Registry will be contacted by the Registry if they may be eligible for a trial or study.

Special Projects:

Through the Patient Registry, PSC Partners is able to conduct special projects of importance to the patient community.

2022 Participation in multinational survey on pruritus in PSC. Results presented at International Liver Congress.

2020 PFDD: Externally-led Patient Focused Drug Development Meeting on PSC with FDA

2020 Diet in PSC Survey (DOCK) - Active Now

2020 Diet in PSC Study (DINER) - Active Now

2020 Covid & PSC Survey - Active and Ongoing

2018 Presentation on PSC Databases at the PSC Forum Meeting 2

2018 Emerging Trends Conference: The Patient Perspective: Insights on Clinical Trial Participation and Retention from the PSC Partners Community

2017 Registry Information Informs PSC & PBC "Call to Action" Education Campaign

2015 Trial Design and Endpoints for Clinical Trials in Adults and Children with Primary Sclerosing Cholangitis: GREAT Workshop, AASLD-FDA Collaborative. Presentation of Registry Participants Survey Responses

History of Collaboration:

The PSC Partners Patient Registry has worked, or is working with, to provide the patient voice and support recruitment support. 

  • Ipsen Pharmaceuticals

  • Chemomab Therapeutics

  • Mirum Pharmaceuticals

  • Pliant Therapeutics

  • Escient Pharmaceuticals

  • HighTide Therapeutics

  • Gilead Sciences

  • CymaBay Therapeutics

  • NGM Biopharmaceuticals

  • Takeda Pharmaceuticals

  • Intercept Pharmaceuticals

  • Lumena Pharmaceuticals

  • Shire Pharmaceuticals

  • Durect Pharmaceuticals

  • Tobira Therapeutics

  • Conatus Pharmaceuticals

  • GlaxoSmithKline (GSK)

  • Patara Pharma

  • Albireo Pharma

bottom of page